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Chapter 22
Inhibition of Bacterial Adhesion on Medical
Devices
Lígia R. Rodrigues
Abstract Microbial infections resulting from bacterial adhesion to biomaterial sur-
faces have been observed on almost all medical devices. Biofilm infections pose
a number of clinical challenges due to their resistance to immune defence mech-
anisms and antimicrobials, and, regardless of the sophistication of the implant, all
medical devices are susceptible to microbial colonisation and infection. Research
efforts are currently directed towards eliminating or reducing infection of medical
devices. Strategies to prevent biofilm formation include physiochemical modifica-
tion of the biomaterial surface to create anti-adhesive surfaces, incorporation of
antimicrobial agents into medical device polymers, mechanical design alternatives,
and release of antibiotics. Nevertheless, the success of these alternatives has been
modest, mainly due to the various environments into which devices are placed and
the diversity of ways in which organisms can colonise surfaces. Biosurfactants have
been reported as a promising strategy as they effectively inhibit bacterial adhesion
and retard biofilm formation, and are thus potentially useful as a new generation of
anti-adhesive and antimicrobial coatings for medical devices.
22.1 Introduction
Microbial adhesion and biofilm formation on medical devices is a common event
that can have important medical and economic consequences. The use of temporary
or permanent implants or prosthetic devices fabricated from polymeric biomateri-
als has increased dramatically in recent years. It is estimated that over 5 million
medical devices or implants are used per year in the United States alone (Bryers,
2008). Medical devices are responsible for about 60–70% of hospital-acquired
infections, particularly in critically ill patients (Bryers, 2008; Darouiche, 2001).
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Bacterial colonisation of an indwelling device, followed by biofilm formation, can
be a prelude to infection and consequently to tissue destruction, systemic dissemi-
nation of the pathogen and dysfunction of the device, resulting in serious illness and
death (Hall-Stoodley et al., 2004). The process by which microorganisms colonise
open and closed implants or prosthetic devices is fairly complicated and involves a
series of steps starting with deposition of host substances (macromolecules such
as collagen and fibronectin) onto the material (Costerton et al., 1999). Device-
associated infections are resistant to immune defence mechanisms and are difficult
to treat with antimicrobial agents because the organisms are encased within a pro-
tected microenvironment hampering the prevention and treatment of established
biofilms (Habash and Reid, 1999). Bacteria that grow in association with medi-
cal devices always form slime-enclosed biofilms within which they are protected, to
a large extent, from the bactericidal activity of chemical biocides and antibiotics.
Removal of the device may be necessary, resulting in both attendant distress to
the patient and cost. Considerable research endeavour is currently directed towards
reducing, if not eliminating, infection of medical devices. Strategies under inves-
tigation include physiochemical modification of the biomaterial surface to create
anti-adhesive surfaces, incorporation of antimicrobial agents into medical device
polymers and the use of electric fields to improve antibiotic therapy (Darouiche,
2001; Hall-Stoodley et al., 2004; Hetrick and Schoenfisch, 2006). Nevertheless, the
efforts to reduce adhesion using specially developed materials, with hydrophilic or
heparin coated surfaces, have had only modest clinical success (Habash and Reid,
1999). The reason, at least for the most part, is the various environments into which
devices are placed and the diversity of ways in which organisms colonise surfaces.
A better understanding of the process is required, as well as the development of
new alternatives to the traditional surface-modifying preventive approaches, which
have largely focused on antimicrobial coating of devices and on employment of
antibiotics (Darouiche, 2001; Habash and Reid, 1999).
This chapter focuses on adhesion and biofilm formation by bacteria on med-
ical devices, strategies to inhibit bacterial adhesion and the potential use of
biosurfactants as anti-adhesive and antimicrobial surface coatings.
22.2 Medical Biofilms
More than half of the infectious diseases that affect mildly immune-compromised
individuals involve bacterial species that are commensal in humans or are com-
mon in our environment (Costerton et al., 1999). For example, the skin bacterium
Staphylococcus epidermidis and the soil bacterium Pseudomonas aeruginosa can
cause devastating chronic infections in immune-compromised hosts. Microbial
infections have been observed on most, if not all, medical devices or implants
including: prosthetic heart valves, orthopaedic implants, intravascular catheters, arti-
ficial hearts, left ventricular assist devices, cardiac pacemakers, vascular prostheses,
cerebrospinal fluid shunts, urinary catheters, voice prostheses, ocular prostheses and
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contact lenses, and intrauterine contraceptive devices (Bryers, 2008; Darouiche,
2001; Rodrigues et al., 2007). In non-surgical indwelling medical devices, such
as central venous and urinary catheters, biofilm colonisation may originate either
from the skin at the point of insertion, or by migration of the organism(s) through
or around the catheter once implanted. As for surgical devices, tissue damage and
clot formation associated with surgical implantation are correlated with enhanced
rates of microbial biofilm colonisation (Donlan and Costerton, 2002; Hetrick and
Schoenfisch, 2006; Lynch and Robertson, 2008; Zilberman and Elsner, 2008). At
the cellular level, implant-associated infections are the result of bacterial adhesion to
a biomaterial surface. Upon implantation, there is competition between integration
of the material into the surrounding tissue and adhesion of bacteria to the implant
surface (Gristina, 1987). For a successful implant, tissue integration occurs prior
to appreciable bacterial adhesion, thereby preventing colonisation at the implant.
However, host defences often can not prevent further colonisation if bacterial adhe-
sion occurs before tissue integration (Gristina, 1987). A 6 h post-implantation
“decisive period” has been identified during which prevention of bacterial adhe-
sion is critical to the long-term success of an implant (Poelstra et al., 2002). Over
this period, an implant is particularly susceptible to surface colonisation. Virtually
all medical devices or tissue engineering constructs are susceptible to microbial
colonisation and infection (Castelli et al., 2006).
Upon adhesion to a surface, replicating adherent bacteria secrete mostly insol-
uble gelatinous exopolymers, forming a biofilm (Bryers, 2008; Darouiche, 2001).
From a medical perspective, both commensal and pathogenic microorganisms form
biofilms that are associated with the epithelial or endothelial lining: embedded in
the lung, intestinal or vaginal mucus layer; attached to the teeth or medical implant
surfaces; or formed intracellularly (Costerton et al., 1999; Hall-Stoodley et al.,
2004; Pizarro-Cerdá and Cossart, 2006; Reid 1999). Microorganisms involved in
biofilms related to human infections are compiled in Lynch and Robertson (2008).
Biofilm formation and persistence has profound implications for the patient, because
microorganisms growing as biofilms are significantly less susceptible to antibiotics
and host defenses than the planktonic forms of the same microorganisms (Bryers,
2008; Costerton et al., 1999). Sessile bacterial cells release antigens and stimulate
the production of antibodies, but the antibodies are not effective in killing bacte-
ria within biofilms and may cause damage to surrounding tissues (Costerton et al.,
1999). Even in individuals with excellent cellular and humoral immune reactions,
biofilm infections are rarely resolved by host defence mechanisms and commonly
manifest themselves as chronic or recurrent infections (Bryers, 2008; Costerton
et al., 1999; Gristina, 1987; Gottenbos et al., 2004). Biofilm infections constitute
a number of clinical challenges, including disease, chronic inflammation, impaired
wound healing, rapidly acquired antibiotic resistance, and the spread of infectious
emboli (Bryers, 2008; Hall-Stoodley et al., 2004; Pizarro-Cerdá and Cossart, 2006).
A number of physical, biological and chemical processes are involved in biofilm
formation, with the relative contribution of each changing throughout biofilm devel-
opment and depending on environmental and hydrodynamic conditions (Habash
and Reid, 1999; Hall-Stoodley et al., 2004). Therefore, non-fouling biomaterials
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ought to be developed; otherwise protein deposition onto the surfaces will occur
with subsequent microbial adhesion and biofilm formation.
22.3 Prevention of Medical Device-Associated Infections
Prophylactic use of antibiotics and biocides can reduce the incidence of biofilm-
associated infections with indwelling medical devices (Lynch and Robertson, 2008).
Strategies to prevent biofilm formation range from systemic approaches controlling
any bacterial invasion of sterile sites to local biofilm inhibition on medical devices
(Fux et al., 2003). The latter focuses on the elimination of planktonic cells before
they adhere to the surface and initiate biofilm formation. Both material proper-
ties and host factors determine bacterial adhesion to medical devices (Rodrigues
et al., 2004a, 2006b, c, 2007). Bacterial adherence to silicone, for example, has
been found to be significantly higher than to polyurethane or Teflon R© (Lopez-
Lopez et al., 1991). Host factors, such as fibronectin, fibrinogen or platelets may
be deposited on the foreign body material and provide specific ligands for bacterial
adhesins (Shenkman et al., 2002). A variety of approaches have proven to be effec-
tive in reducing biofilm-related infections by preventing bacterial adhesion, at least
in high-risk populations (Fux et al., 2003). They include device coatings, device
immersion, anti-septic irrigation of the surgical site, antibiotic loaded cements in
orthopedic surgery (Zilberman and Elsner, 2008), and antibiotic catheter lock ther-
apy containing vancomycin and heparin (Carratalà et al., 1999) or minocycline and
EDTA (Raad et al., 2002). In antibiotic catheter lock therapy, a concentrated antibi-
otic solution is placed in a catheter in a volume adequate to fill the lumen. The
catheter is then “locked” into place for an extended period while the catheter is not
in use, with the goal of preventing it from becoming colonised and thereby reducing
the risk of infection (Lynch and Robertson, 2008). Impregnation of catheter sur-
faces with antiseptics (Veenstra et al., 1999) or antibiotics (Zilberman and Elsner,
2008) has been shown to delay bacterial colonisation. Although the use of antibiotic
prophylaxis is controversial because of its potential to increase antimicrobial resis-
tance, it is increasingly common in high-risk patient groups (Lynch and Robertson,
2008). With regard to device coatings, Falagas and co-workers (2007) conducted a
recent and comprehensive meta-analysis of randomised controlled trials of rifampin-
impregnated central venous catheters and found that they are both safe and effective
in reducing the rate of catheter colonisation and catheter-related bloodstream infec-
tions. Similarly, Manierski and Besarab (2006) performed six independent studies
on the efficacy of antibiotic lock therapy in the prevention of catheter-related blood-
stream infections in haemodialysis patients, and found an overall reduction of
64–100% in catheter-related bloodstream infections.
Furthermore, Rodrigues and collaborators (2004, 2006b, c, 2007) have shown
that impregnation of silicone rubber surfaces with biosurfactants produced by sev-
eral lactobacilli inhibits the adhesion of several microorganisms. In the specific
case of voice prostheses, it is well-known that biofilms are resistant to a range of
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antifungal agents currently in clinical use, including amphotericin B and flucona-
zole, thus new prophylactic treatments are being explored to prolong their lifetime.
As antimicrobial resistance is becoming a source of concern in modern medicine
and health-improving functional foods are gaining in popularity, the development of
alternative prophylactic and therapeutic agents, including probiotics, has been inves-
tigated (Free et al., 2001). Lactobacilli are one of the most well-known probiotic
bacterial genera and play an important role in the maintenance of a healthy intestinal
and urogenital tract (Velraeds et al., 1998; Reid, 1999, 2000). Other bacterial gen-
era known to have probiotic effects are Lactococci, Enterococci and Streptococci.
The mechanisms by which probiotic bacteria exert their beneficial effects are not
yet entirely understood. Possible mechanisms are competitive adhesion (Busscher
et al., 1997), activation of the immune system (Perdigon et al., 1986), or nutrient
competition (Free et al., 2001). Some strains are able to release biosurfactants, while
others are known to have antimycotic effects by producing lactic acid or hydrogen
peroxide.
22.4 Treatment of Medical Device-Associated Infections
Traditional treatment of microbial infections is based on compounds that inhibit
growth of the microbe or kill it (Bryers, 2008). The major concern with this
approach is the frequent development of resistance to antibiotics. For details on
agents for treatment or prophylaxis of biofilm-associated infections, the reader
is directed to the review by Lynch and Robertson (2008). Bacterial biofilms are
inherently resistant to antimicrobial agents and the host immune system, and tend
to be significantly less responsive to antibiotics and antimicrobial stressors than
planktonic organisms of the same species (Bryers, 2008; Costerton et al., 1999).
Prolonged and high-dose antibiotic therapy and the elimination of infected foreign-
body material are the basis of successful therapy. Antibiotic treatment of bacterial
endocarditis was shown to be more successful when serum antibiotic levels were
held at least tenfold above the minimal bactericidal concentration (Joly et al., 1987);
but even with 8 weeks of treatment, few patients have been cured by antimicrobial
therapy alone (Hancock, 1994). The combination of rifampicin and a fluoroquinone
has proven especially successful in the treatment of various S. aureus biofilm infec-
tions, ranging from infections of orthopaedic prostheses (Habash and Reid, 1999)
to right-heart endocarditis (Heldman et al., 1996). On the other hand, the study
reported by Bagge and co-workers (2004) showed that sub-lethal doses of β-lactam
antibiotic can actually enhance biofilm formation by P. aeruginosa, increasing
its volume and polymer matrix, which can lead to adverse consequences when
treating cystic fibrosis patients. Also, Hoffman et al. (2005) reported that sub-
inhibitory concentrations of aminoglycoside antibiotics induced biofilm formation
by P. aeruginosa and E. coli.
As a consequence of this increase in resistance, researchers have turned to a
number of alternatives to synthetic antibiotics including disinfectants (Hetrick and
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Schoenfisch, 2006; Zilberman and Elsner, 2008), bacteriophage (Sulakvelidze et al.,
2001) and bacteriophage lytic enzymes (Fischetti, 2005), probiotics (Hong et al.,
2005), and human antimicrobial peptides (defensins, cathelicidins, and histatins)
(De Smet and Contreras, 2005). Nevertheless, these are mostly synthetic compounds
with the ability to inactivate or kill suspended bacteria but with poor efficacy when
applied to biofilm infections (Stewart, 2002). It has been recently proposed that
substances that specifically inhibit bacterial virulence should be developed. Such
“antipathogenic” drugs, in contrast to antibacterial drugs, do not kill bacteria or
stop their growth and are assumed not to lead to the development of resistant strains
(Bryers, 2008). A very elegant approach comprises the inhibition of regulatory
systems that govern the expression of a series of bacterial virulence factors: for
example, anti-adhesion therapy [passive antibody therapy (Casadevall et al., 2004),
and synthetic peptide vaccine and antibody therapy (Cachia and Hodges, 2003)],
inhibition or negation of cell–cell signalling (Otto, 2004), negation of biofilm for-
mation by disrupting iron metabolism (Kaneko et al., 2007), and up-regulation of
biofilm detachment promoters (rhamnolipids) (Boles et al., 2005).
Replacement or removal of an infected indwelling medical device, combined
with systemic antibiotic and/or antifungal therapy, is the most effective treat-
ment in most settings (Trampuz and Zimmerli, 2006). For managing indwelling
medical device infections in non-surgery patients, long-term antimicrobial sup-
pressive therapy remains the only option (Lynch and Robertson, 2008). Recent
reviews summarise current recommended practices for the treatment of infections
of prosthetic joints (Trampuz and Zimmerli, 2006), arterial prostheses (Goeau-
Brissonnière and Coggia, 2000), vascular catheters (Castelli et al., 2006), prosthetic
heart valves (Karchmer, 2000), central nervous system shunts (Yogev and Bisno,
2000), pacemakers and defibrillators (Eggimann and Waldvogel, 2000), endotra-
cheal and tracheotomy tubes (Dever and Johanson, 2000), and hemodialysis and
peritoneal hardware (Oliver and Schwab, 2000), as well as treatment of foreign body
infections of the urinary tract (Hessen et al., 2000).
22.5 Development of Anti-adhesive Biomaterials
The remarkable resistance of biofilms to conventional antibiotic therapy has
prompted a great deal of research to produce anti-infective and anti-adhesive
devices or implants by either (a) mechanical design alternatives, (b) modifica-
tion of material surface features (biosurfactants, plasma, brushes), (c) anti-infective
agents bound to the surface of the material (silver, quaternary ammonium, synthetic
antibiotics, biosurfactants), or (d) release of soluble toxic agents (chlorhexidine,
antibiotics) into the adjacent surroundings (Bryers, 2008; Hetrick and Schoenfisch,
2006). Mechanical design alternatives have had only marginal success and are only
applicable for short-term indwelling catheters (Bryers, 2008). Coatings have been
developed that reduce bacterial adhesion by altering the physicochemical proper-
ties of the substrate so that conditioning films do not form and/or bacteria-substrate
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interactions are not favoured. These “passive” coatings include surfaces modified
with poly(ethylene glycol) (Kingshott et al., 2003), poly(ethylene oxide) brushes
(Kaper et al., 2003), and hydrophilic polyurethanes (Nagel et al., 1996), among
many others. Unfortunately, the effectiveness of passive coatings for reducing bac-
terial adhesion is limited and varies greatly depending on the bacterial species
(Hetrick and Schoenfisch, 2006). The physicochemical properties of the coating
can be masked by an adsorbed conditioning film, thereby diminishing their effec-
tiveness. Additionally, surface-bounded anti-infective agents are only toxic to the
initial wave of incoming bacteria and provide little residual effects once layers of
dead cells accumulate, which are also inflammatory (Bryers, 2008). Nevertheless,
there are studies pointing to some success in retarding bacterial adhesion, which in
turn inhibits or delays biofilm formation. One specific example is the development
of anti-adhesive silicone rubber surfaces for voice prostheses. Voice prostheses are
continuously exposed to saliva, food, and drinks that, together with the oropha-
ryngeal microflora, contribute to valve failure and the need to replace the implant
frequently (Mahieu et al., 1986). Therefore, improvement of the antifouling proper-
ties of the silicone rubber material is desirable. Rodrigues and collaborators (2007)
reviewed the different approaches that have been undertaken to modify the silicone
rubber surface as an obvious strategy to inhibit biofilm formation and consequently
to prolong the lifetime of voice prostheses.
A recent alternative approach to reducing bacterial adhesion is based on coat-
ings that actively release antibacterial agents. Such “active” coatings have been
designed to temporarily release high initial fluxes of antibacterial agents during the
critical short term post-implementation period (several hours) to inhibit adhesion
of bacteria. Continued release beyond this short term period is desirable because
protective fibrous capsule formation and tissue integration occur over a longer
time period (weeks to months) (Anderson, 2001). Zilberman and Elsner (2008)
reviewed the latest developments on antibiotic-eluting medical devices for various
applications.
For example, non-degradable polymethylmethacrylate (PMMA) bone cements
and spacer beads loaded with antibiotics have been employed clinically in various
forms in joint replacements and in prevention or treatment of deep bone infections
(osteomyelitis) (Webb and Spencer, 2007). Such systems slowly release the soluble
drug from the solidified PMMA bone cement surrounding the implant over time.
Moreover, the use of a bioactive ceramic coating containing hydroxyapatite (HA),
calcium phosphate and other osteo-conductive materials as antibiotic carriers offers
the added value of providing the physiochemical environment and structural scaffold
required for bone-implant integration. In vitro release of antibiotics from HA-coated
implants has been reported for several antibiotics (Teller et al., 2007). The conven-
tional plasma spraying technique for HA-coating is associated with high processing
temperatures and therefore does not enable the incorporation of antibiotics in the
process. Most reported work therefore focuses on soaking antibiotics onto plasma-
sprayed HA. Gollwitzer and collaborators (2003) studied biodegradable polymeric
coatings made from polylactic acid and its copolymers with glycolic acid. An addi-
tional advantage of such coatings is the relative ease with which the polymer can be
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applied to both alloys and plastics with polished, irregular or porous surfaces using
a simple dip-coating technique (Schmidmaier et al., 2006).
Other examples of antibiotic-eluting medical devices include intravascular
devices and vascular grafts. Infection of intravascular devices for vascular access
and vascular prostheses for the replacement or bypass of damaged arteries is a rare
but serious event (Zilberman and Elsner, 2008). The infection of a vascular graft
is a rare complication, with an estimated incidence of 0.5–2.5% of bypass proce-
dures. However, the mortality and morbidity rates due to this complication are high
(Bryers, 2008). Once a prosthetic graft is infected, it must almost always be excised
and replaced with a new prosthetic bypass. The development of infection-resistant
vascular prostheses may therefore contribute to the prevention and treatment of
this complication. PET (polyethyleneterephtalate, DacronTM) and ePTFE (expanded
polytetrafluorethylene) vascular prostheses soaked in an antibiotic solution pro-
duce a wash-out release of antibiotics within minutes after placement (Blanchemain
et al., 2005). Several approaches have been proposed for extending release over
days and weeks. Antibiotics have been “bonded” by soaking collagen, albumin,
and gelatin sealed grafts to produce extended antibacterial activity (Zilberman and
Elsner, 2008).
Finally, regardless of the type of “drug release” method used (passive versus
active), release of a toxic agent from a biomaterial of a soluble anti-infective agent
will inevitably stop once the entrapped agent is depleted. Further, as discussed
above, delivery of sub-lethal dosages of antibiotics can lead to accelerated biofilm
formation and induced virulence factor expression (Bryers, 2008).
22.6 Biosurfactants: A Powerful Tool to Inhibit
Bacterial Adhesion
Biosurfactants are microbial amphiphilic compounds with both hydrophilic and
hydrophobic moieties and with a distinct tendency to accumulate at interfaces. For
all interfacial systems, it is known that organic molecules from the aqueous phase
tend to immobilise at the solid interface. There they eventually form a conditioning
film, which will change the properties (wettability and surface energy) of the origi-
nal surface (Neu, 1996). In an analogy to organic conditioning films, biosurfactants
may interact with the interfaces and affect the adhesion and/or detachment of bac-
teria. In addition, the substratum surface properties determine the composition and
orientation of the molecules conditioning the surface during the first hour of expo-
sure. After about 4 h, a certain degree of uniformity is reached and the composition
of the adsorbed material becomes substratum-independent (Neu, 1996). Adsorption
of charged biosurfactants to interfaces is governed by a range of interactions that are
not only hydrophobic. Most interfaces have an overall negative or, rarely, positive
charge. Gottenbos et al. (2001) showed that positively charged biomaterial surfaces
exert an antimicrobial effect on adhering Gram-negative, but not on Gram-positive
bacteria.
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Microbial surfactants constitute a diverse group of surface-active molecules and
are known to occur in a variety of chemical structures, such as glycolipids, lipopep-
tides and lipoproteins, fatty acids, neutral lipids, phospholipids, and polymeric and
particulate structures (Rodrigues et al., 2006a). Their use and potential commercial
application in the medical field has increased during the past decade (Muthusamy
et al., 2008; Rivardo et al., 2009; Rodrigues et al., 2006a), due to their antibac-
terial, antifungal and antiviral activities, which make them useful for combating
many diseases and as therapeutic agents. In addition, their role as anti-adhesive
agents against several pathogens indicates their utility as suitable anti-adhesive coat-
ing agents for medical insertional materials, leading to new and effective means of
combating colonisation by pathogenic microorganisms without the use of synthetic
drugs and chemicals (Rodrigues et al., 2006a). Mireles and collaborators (2001)
pre-coated vinyl urethral catheters by running the surfactin solution through them
before inoculation with media and found a decrease in the amount of biofilm formed
by Salmonella Typhimurium, Salmonella enterica, E. coli and Proteus mirabilis.
Moreover, the use of lactobacilli as a probiotic for the prevention of urogenital
infections has been widely studied (Reid, 2000; Boris and Barbés, 2000). Velraeds
et al. (1998) reported the inhibition of biofilm formation by uropathogens and
yeast on silicone rubber with biosurfactants produced by Lactobacillus acidophilus.
Also, Heinemann et al. (2000) showed that Lactobacillus fermentum RC-14 releases
surface-active components that can inhibit adhesion of uropathogenic bacteria.
Efforts to develop strategies to prevent the microbial colonisation of silicone rubber
voice prostheses have been reported by Rodrigues and co-workers (2004a, 2006c).
Biosurfactants obtained from Lactococcus lactis 53 and Streptococcus thermophilus
A have been evaluated as anti-adhesive agents against several microorganisms
isolated from explanted voice prostheses. Over 90% reductions in the initial depo-
sition rates were achieved for most of the bacterial strains tested. The biosurfactant
obtained from S. thermophilus A was more effective against Rothia dentocariosa
GBJ 52/2B, which is one of the strains responsible for valve prosthesis failure.
Nevertheless, the effect of the adsorbed biosurfactant was less pronounced for the
initial deposition rates of the yeast strains. The authors also demonstrated that, when
rinsing flow chambers designed to monitor microbial adhesion with a rhamnolipid
solution, the rate of deposition and adhesion was significantly reduced for a variety
of microorganisms (Rodrigues et al., 2006a, b). Thus, this rhamnolipid may be use-
ful as a biodetergent solution for cleaning prostheses, prolonging their lifetime and
directly benefiting laryngectomised patients.
Furthermore, the biosurfactants produced by the same strains (Rodrigues
et al., 2004b) and by Lactobacillus paracasei ssp. paracasei A20 (Gudiña et al.,
2010a, b) were found to possess antimicrobial and anti-adhesive activity against
several microorganisms. For contact lenses (CL), maintaining the optical properties
might limit the use of biosurfactants as coating agents. Consequently, Rodrigues
and collaborators evaluated the influence of biosurfactants on refractive index (RI)
and transmittance (T) (unpublished data). One conventional hydrogel (Etafilcon A)
and two silicone-hydrogel (Galyfilcon and Lotrafilcon B) contact lenses were tested
(Table 22.1). Prior adsorption of biosurfactants to silicone-hydrogel lenses had no
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Table 22.1 Refractive index and transmittance in the visible spectrum of contact lenses with
and without an absorbed biosurfactant layer. Biosurfactants from Lactococcus lactis (BS1),
Lactobacillus paracasei ssp. paracasei A20 (BS2) and Streptococcus thermophilus A (BS3) were
tested at 2 different concentrations (10 and 50 g/L). One conventional hydrogel CL (Etafilcon A)
and two silicone-hydrogel (Galyfilcon and Lotrafilcon B) lenses were used. Experiments were done
in triplicate. Refractive index values correspond within 1–2% and transmittance values correspond
within 2–5%
Treatment with biosurfactant
BS1 (g/L) BS2 (g/L) BS3 (g/L)
Contact lenses 10 50 10 50 10 50
Untreated
contact lenses
Refractive index Galyfilcon 1.408 1.411 1.408 1.409 1.410 1.411 1.408
Lotrafilcon B 1.422 1.424 1.423 1.423 1.422 1.424 1.422
Etafilcon A 1.414 1.436 1.406 1.418 1.408 1.418 1.398
Transmittance in the Galyfilcon 86.2 82.8 89.7 88.5 83.0 82.2 91.0
visible spectra (%) Lotrafilcon B 82.4 80.1 85.8 81.5 82.5 81.6 83.9
Etafilcon A 90.3 86.5 89.1 88.9 90.2 81.6 88.7
effect on the RI. However, for the biosurfactant-conditioned hydrogel CL, a higher
RI was obtained compared to the untreated lenses. This increase in RI is a conse-
quence of the dehydration observed with the adsorption of the biosurfactants, which
is not desirable. All treated contact lens types showed a decrease in transmittance
levels in the visible spectra, the effect being more pronounced for higher biosurfac-
tant concentrations as a result of their colour. Although the results obtained for the
transmittance experiments were promising, further characterisation and purification
of the biosurfactants is required to enable the use of lower concentrations, more
active and colourless fractions.
In another study, the same authors explored the possibility of using the biosur-
factant produced by S. thermophilus A to pre-condition silicone rubber surfaces
to inhibit the adhesion of the two most frequent fungi isolated from maxillofa-
cial prostheses, Candida albicans MFP 22-1 and Candida parapsilosis MFP 16-2
(unpublished data). Adhesion assays showed a reduction of 60–80% in the ini-
tial deposition rates (Fig. 22.1). These results represent progress towards designing
new strategies for preventing microbial adhesion to silicone rubber maxillofacial
prostheses.
Besides the screening of lactobacilli as biosurfactant producers, Rodrigues
and collaborators (2006d) also characterised the anti-adhesive activity of these
biosurfactants against several microorganisms including Gram-positive and Gram-
negative bacteria and filamentous fungi (Gudiña et al., 2010a, b). For example, the
biosurfactant produced by L. paracasei A20 showed anti-adhesive activity against
Streptococcus sanguis (72.9%), S. aureus (76.8%), S. epidermidis (72.9%) and
Streptococcus agalactie (66.6%) (Gudiña et al., 2010a). Additionally, the anti-
adhesive activity of two biosurfactants produced by Candida sphaerica UCP 0995
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Fig. 22.1 (a) Initial deposition rates (j0, cm–2 s–1) of Candida parapsilosis MFP 16-2 and Candida
albicans MFP 22-1 isolated from maxillofacial prostheses on Sylgard R©184 silicone rubber with
and without an adsorbed biosurfactant (BS) layer; (b) Number of microorganisms adhering after
2 h (n2 h) on Sylgard R©184 with and without an adsorbed biosurfactant (BS) layer. Biosurfactant
was produced by Streptococus thermophilus A, (see Rodrigues et al., 2006c). Results are averages
of triplicate experiments and the standard deviation represented by error bars
and Candida lipolytica UCP 0988 was studied (unpublished data). The biosurfac-
tant from C. sphaerica UCP 0995 was found to inhibit the adhesion of P. aeruginosa,
S. agalactiae, S. sanguis, C. tropicallis, E. coli, and S. salivarius by between 80 and
92%. Inhibition of adhesion with percentages near 100% occurred for the higher
concentrations of biosurfactant used (Table 22.2). Although less pronounced, simi-
lar results were obtained with the biosurfactant produced by C. lipolytica UCP 0988
for some of the microbial strains studied (Fig. 22.2). All these results open prospects
for the use of biosurfactants against the adhesion of microorganisms responsible for
diseases and infections in the urinary, vaginal and gastrointestinal tracts, as well as
in the skin.
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Table 22.2 Anti-adhesive properties of crude biosurfactant produced and extracted from Candida
sphaerica UCP 0095. Negative controls were set at 0% to indicate the absence of biosurfactant.
Positive percentages indicate the reductions in microbial adhesion when compared to the con-
trol, and negative percentages indicate increased microbial adhesion. Results are expressed as
percentage means from triplicate experiments and correspond within 1–3%
[Biosurfactant] (mg/L)
Microorganism 0.3 0.6 2.5 5 10
Candida tropicalis 80 85 87 98 100
Escherichia coli 89 93 96 97 99
Pseudomonas aeruginosa 80 82 83 89 92
Streptococcus agalactiae 80 86 88 92 100
Streptococcus sanguis 80 83 87 98 100
Streptococcus salivarius 92 93 95 97 100
Fig. 22.2 Microbial inhibition percentages obtained from the anti-adhesion assays with the crude
biosurfactant produced by Candida lipolytica UCP 0988 at different concentrations (0.75 mg/L
[], 1.5 mg/L [], 3 mg/L [], 6 mg/L [] and 12 mg/L []). Results are averages of triplicate
assays and error bars represent standard deviations
Based on the above, biosurfactants can play an important role in the development
of anti-adhesive coatings for silicone rubber as they effectively inhibit bacterial
adhesion and retard biofilm formation. Therefore, surface and bulk modification
techniques, laser-induced surface grafting and the sequential method for interpen-
etrating polymer networks should be explored as ways to link the biosurfactants
more strongly with the silicone rubber surfaces, thus avoiding their washout from
the surfaces and prolonging their effect. Furthermore, biosurfactants are a suitable
alternative to antimicrobial agents, and could be used as safe and effective therapeu-
tic agents or probiotics. The use of biosurfactants as antimicrobial agents is currently
of particular interest, since an increasing number of drug-resistant microorganisms
are being encountered and there is a need for alternative lines of therapy. Some
biosurfactant activities could be exploited by developing an alternative therapy for
treating patients (Rodrigues et al., 2006a). Nevertheless, although the replacement
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of synthetic surfactants by biosurfactants would provide advantages such as
biodegradability and low toxicity, their use has been limited by their relatively
high production cost, as well as scarce information on their toxicity in humans.
The main limiting factor, however, for commercialisation of biosurfactants is the
high cost of large-scale production. Several strategies have been adopted to reduce
costs (Rodrigues et al., 2006e). The use of agro-industrial wastes as substrates,
optimisation of medium and culture conditions, and efficient recovery processes
all help. However, to compete with synthetic surfactants, effective microorganisms
must be developed for biosurfactant production. The use of biosurfactant hyper-
producer strains allows increasing biosurfactant production and reduces production
costs. Strains producing higher amounts of biosurfactants can be obtained by screen-
ing high biosurfactant-producing microorganisms from the natural environment, or
by engineering strains for biosurfactant production. Therefore, knowledge of the
genes required for production of biosurfactants is critical for their application in
industry. Once the genes have been indentified and isolated, they can be expressed
in other microorganisms (e.g. to prevent pathogenicity), or they can be modified
or placed under regulation of strong promoters to increase their expression and so
enhance production. This knowledge will also allow the production of novel bio-
surfactants with specific new properties (designed by metabolic engineering) for
different industrial applications. Genetic engineering of the known biosurfactant
molecules could produce potent biosurfactants with altered antimicrobial profiles
and decreased toxicity against mammalian cells.
22.7 Concluding Remarks
The processes governing biofilm formation are rather complex, involving sev-
eral steps and almost all surfaces are susceptible of being colonised. Bacterial
colonisation and subsequent biofilm formation on an indwelling device can lead
to infection with severe economic and medical consequences. Device-associated
infections are resistant to immune defense mechanisms and are difficult to treat with
antimicrobial agents because the organisms are encased within a protected microen-
vironment. Therefore, non-fouling biomaterials ought to be developed. Several
strategies based on the modification of the physicochemical properties of the sub-
strate have been pursued. Nevertheless, the effectiveness of these coatings has been
found to be limited and varies greatly depending on bacterial species, mainly due to
the diverse environments into which the devices are placed and the multiplicity of
ways in which organisms can colonise surfaces. Development of alternatives to the
traditional surface-modifying preventive approaches, which have largely focused
on antimicrobial coating of devices and employment of antibiotics, is required.
Biosurfactants represent an interesting approach because it may be possible to
modify the surface properties to make it simultaneously anti-adhesive and give
it antimicrobial activity. However, although some studies have demonstrated the
potential of biosurfactants in biomedical applications, the genetics and structure-
function relationships of biosurfactants, and methods of binding them to surfaces,
require further exploration.
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